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Effects of Methylprednisolone and Its Liver-Targeted Dextran
Prodrug on Ischemia-Reperfusion Injury in a Rat Liver
Transplantation Model
Anjaneya P. Chimalakonda1,2 and Reza Mehvar1,3
1 School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, Texas, USA
Abstract
Purpose—To evaluate the effectiveness of a liver-targeted dextran prodrug (DMP) of
methylprednisolone (MP) in cold preservation-warm reperfusion injury associated with liver
transplantation.
Methods—The effects of donor pretreatment with single 5-mg/kg doses of MP or DMP on ischemia-
reperfusion damage to the liver were studied after 8 or 24 h of cold preservation in both isolated
perfused rat liver (IPRL) and syngeneic orthotopic rat liver transplantation (OLT) models.
Results—In IPRL studies, donor pretreatment with DMP, and to a lesser degree MP, significantly
improved the uptake of hyaluronic acid (HA), a marker of endothelial cell function, following 8 h
of cold preservation. However, neither pretreatment was protective after 24 h of preservation. In the
OLT model using 24 h-preserved livers, the seven-day survival of untreated grafts was 50%. DMP
pretreatment of donors significantly improved graft survival to 100%, whereas MP pretreatment was
ineffective. Additionally, only DMP significantly increased the blood glucose concentrations and
decreased the plasma concentrations of tumor necrosis factor-α after OLT. Other measured markers
of liver injury were not affected by either pretreatment.
Conclusions—Selective delivery of methylprednisolone to the liver as a donor pretreatment
strategy improves 24-h preserved graft survival in the OLT model.
Keywords
macromolecular prodrug; ischemia-reperfusion injury; isolated perfused rat liver; hepatic
disposition; rat liver transplantation
INTRODUCTION
Despite improvements in organ preservation solutions, ischemia-reperfusion (IR) damage
during the preservation and implantation of the liver is still a major problem in liver
transplantation (1). Although reducing the metabolic state of the liver, the cold ischemic period,
which happens after the explantation of the liver from the donor, by itself causes damage to
the liver (1,2). This damage is mostly due to lack of oxygen that alters energy metabolism,
consequently resulting in a decrease in adenosine triphosphate concentrations, an increase in
cellular edema, and accumulation of intracellular sodium (3). Ironically, provision of oxygen
by reperfusion of the liver after implantation in the recipient causes production of reactive
oxygen species and a number of proinflammatory cytokines, further damaging the organ (1).
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The extent of IR damage is proportional to the ischemic period, and prolonged preservation
and subsequent reperfusion causes hepatocellular injury, which may result in primary graft
nonfunction, requiring retransplantation (2). Given the multi-factorial etiology of IR damage,
therapeutic regimens aimed at one or more levels are required for its successful prevention
and/or treatment (1). However, no such treatment is currently available (1).
We have previously proposed the use of a liver-targeted dextran prodrug of methylprednisolone
(MP) as a donor pretreatment strategy aimed at prevention and/or attenuation of cold IR injury
(4,5). This dextran prodrug of MP (DMP) was shown to selectively accumulate and release the
parent drug MP in the liver and spleen following systemic administration (6). In addition,
pretreatment of donors with DMP, compared with equimolar doses of MP, resulted in superior
attenuation of Kupffer cell (KC) activation (4) and improvement in hepatocyte function (5) in
an ex vivo isolated perfused rat liver (IPRL) model. In addition to KCs and hepatocytes,
sinusoidal endothelial cells (ECs) of the liver are also known to play a critical role in
development of cold IR injury (2). Therefore, the first aim of this study was to assess the effects
of MP and DMP on the function of ECs in an IPRL model of cold ischemia-warm reperfusion
injury. Additionally, IPRL, although a suitable model for relatively short-term mechanistic
studies, cannot replace in vivo studies, which can determine both the short- and long-term
effects of hepatic IR on the overall health of the animal. Therefore, the second aim of the study
was to investigate the effects of pretreatment of donors with DMP or its parent drug MP on
the preservation-induced injury in an in vivo orthotopic rat liver transplantation (OLT) model.
Based on therapeutic potential of DMP, demonstrated in our previous ex vivo experiments, we
hypothesized that DMP pretreatment would decrease hepatocellular damage and improve graft
survival in animals transplanted with livers subjected to cold preservation damage.
MATERIALS AND METHODS
Chemicals
Dextran, with an average molecular weight of 73 kDa and a polydispersity of <2, hyaluronic
acid (HA) from rooster comb, and Purpald (4-amino-3-hydrazino-5-mercapto-1,2,4-triazole)
were obtained from Sigma Chemical Co. (St. Louis, MO). Belzer's University of Wisconsin
(UW) solution (Viaspan) was obtained from Dupont Pharma (Wilmington, DE). 6α-
Methylprednisolone 21-hemisuccinate sodium was obtained from Steraloids, Inc. (Newport,
RI). An enzyme linked binding protein assay kit for measurement of HA was obtained from
Corgenix, Inc (Westminster, CO). Enzyme-linked immunosorbent assay (ELISA) kit for
measurement of tumor necrosis factor (TNF)-α was purchased from Biosource International,
Inc. (Camarillo, CA). Kits for determination of aspartate aminotransferase (AST) and alanine
aminotransferase (ALT) were purchased from Teco Diagnostics (Anaheim, CA). Automated
blood glucose measurement kit (Onetouch Ultra®) was obtained from Lifescan, Inc (Milpitas,
CA).
Dextran–methylprednisolone succinate (DMP) was synthesized, purified, and characterized as
described before (7). The MP and MPS impurities in the conjugate powder were less than 0.1%
(w/w), and the degree of substitution of the powder was 8 mg of MP per 100 mg of powder.
The MP (as its sodium succinate salt) and DMP dosing solutions were prepared in saline
immediately before drug administration.
Animals
A total of 115 male Sprague-Dawley rats were used in this study. Animals were purchased
from a commercial source and housed in a humidity- and temperature-controlled room under
a 12 h-light/dark cycle. Rats were provided with food and water ad libitum throughout the
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period of the study. All the procedures involving animals in this study were consistent with
the “Principles of Laboratory Animal Care” (NIH publication #85−23, revised 1985) and
approved by the Texas Tech University Health Sciences Center Institutional Animal Care and
Use Committee.
Effect of MP or DMP Pretreatment on Endothelial Cell Function in an IPRL Model
Twenty five Sprague-Dawley rats weighing 225−250 g were used as liver donors for these
studies and divided into 7 groups (n=3−4/group). Two groups were used for testing the effect
of MP following 8 (MP-8) or 24 (MP-24) h of cold preservation. Similarly, two groups were
used to assess the effect of DMP following 8 (DMP-8) or 24 (DMP-24) h of preservation.
Corresponding untreated groups (Control-8 and Control-24) were included as references.
Additionally, a second control group with no cold preservation (Unpreserved) was included in
this study to determine the disposition of HA in fresh livers. Rats were given a single 5-mg/kg
(MP equivalent) dose of MP or DMP or an equal volume of saline (Control) via their tail vein.
Two hours following drug or saline administration, livers were perfused and stored in UW
solution for 8 or 24 h at 4°C. The techniques used for isolation, cannulation and harvest of
livers were reported by us before (4,8). Following 8 or 24 h of cold preservation, the livers
were washed with 20 ml of lactated Ringer's solution to remove the UW solution. Then, the
livers were reperfused in a water-jacketed, all-glass perfusion system (Radnoti Glass
Technology Inc., Monrovia, CA) kept at 37°C. The perfusate was Krebs-Henseleit bicarbonate
buffer (pH 7.4) fortified with 1.2 g/l glucose and 4.75 mg/l of sodium taurocholate, which was
oxygenated with a 95:5 oxygen:carbon dioxide mixture. The perfusate flow rate was
maintained at 30 ml/min (3−4 ml/min/g of liver weight). Immediately following reperfusion,
the livers were allowed to stabilize for 10 min before start of the experiment. Subsequently,
HA was added to the perfusate to attain an initial concentration of 50−60 ng/ml, and the
perfusion was continued in a recirculating manner (reservoir volume = 150 ml) for 70 min.
Samples (∼ 1 ml) were collected periodically from the perfusate reservoir and stored at −80°
C until analysis. Bile was collected in preweighed micro-centrifuge tubes.
Effect of MP or DMP on Cold Preservation-Reperfusion Injury following OLT
Ninety rats resulting in 45 transplanted animals were used in these studies. Sprague-Dawley
rats were used as both donors (240−280 g) and recipients (280−320 g) for the transplantation
procedure. This syngeneic model, which is devoid of immunologic rejection, has been used
before by other investigators to study IR damage (9,10). Donor rats were administered a single
intravenous 5-mg/kg dose of MP or DMP via the penile vein 2−3 h before liver isolation.
Control rats received an equal volume of saline. A non-arterialized model of liver
transplantation was performed by modification of Kamada's technique (11), as reported by us
recently (12). Briefly, after removal of the livers from the donors, grafts were perfused with
10 ml of cold (4°C) UW solution and cuffs were mounted on the portal vein, infra-hepatic vena
cava, and supra-hepatic vena cava. Liver grafts were stored in 40 ml of UW solution maintained
at 4°C for 24 h. Following the hepatectomy of the recipient liver, the graft was placed in an
orthotopic position and anastomoses of all the three veins were completed by the cuff technique.
Given that the post-operative survival following OLT of preserved livers is largely dependent
on the portal venous clamping time (13), the anhepatic period was fixed to 19 min in all the
experiments.
Twenty four transplanted rats were used for the graft survival study, resulting in 8 transplants
in each of the control, MP, and DMP groups. Animals surviving greater than 7 days were
considered as long-term survivors. Additional 21 transplanted animals were used to monitor
biochemical parameters. In these studies, transplanted rats receiving MP-, DMP-, or vehicle-
treated livers were euthanized at either 1 or 6 h following OLT (n=3−4 transplants/group/time
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point). Blood was collected and centrifuged to separate the plasma and stored at −80 °C until
further analysis.
Sample Analysis
Blood glucose was measured following completion of transplantation procedure with an
automated analyzer. Plasma concentrations of TNF-α, HA, ALT, and AST were estimated
spectrophotometrically using commercially available kits, according to the instructions of the
manufacturers.
Data Analysis
For the isolated perfused rat liver studies, the area under the perfusate HA concentration-time
curve (AUC) was calculated using trapezoidal rule (0−70 min), with extrapolation to infinity
using the terminal first-order rate constant (k). The terminal half life (t1/2), hepatic clearance
(Clh), and extraction ratio (E) of HA were calculated using the following equations:
t 1
2
= 0.693k (1)
Clh =
Dose
AUC (2)
E =
Clh
Q (3)
where Dose is the total dose of hyaluronic acid in the recirculating system and Q is the perfusate
flow rate.
Statistical Analysis
The effects of drug pretreatments (Control, MP, or DMP) on the kinetics of HA following
isolated liver perfusion and on the blood glucose concentrations immediately following OLT
were assessed using a one-way ANOVA with a Fisher's post-hoc test. The statistical evaluation
of differences in the graft survival was performed using the log rank test applied to Kaplan-
Meier plots. The effects of drug treatment and reperfusion time on the plasma concentrations
of TNF-α, HA, ALT, and AST were evaluated by a two-way ANOVA with Fisher's post hoc
analysis. All tests were performed at a significance level (α) of 0.05. Data are presented as
mean ± S.D.
RESULTS
Effect of MP or DMP Pretreatment on Endothelial Cell Function in an IPRL Model
The plots of perfusate concentrations of HA against perfusion time in the control and treated
groups are shown Fig. 1. Hyaluronic acid concentrations in the perfusate followed a mono-
exponential decline in the Unpreserved and the 8-h preserved groups (Fig. 1, top). HA was
rapidly taken up by Unpreserved livers, and its concentrations could not be measured after 30
min of perfusion. Compared with Unpreserved livers, preservation of livers for 8 h resulted in
a slower decline in HA concentrations, indicating decreased function/viability of the ECs (Fig.
1, top panel). Both MP (MP-8) and DMP (DMP-8) pretreatment resulted in faster declines in
the concentrations of HA in the perfusate, compared with vehicle pretreatment (Control-8)
(Fig. 1, top panel). In contrast to the 8-h preservation groups (Fig. 1, top), untreated livers
preserved for 24 h (Control-24) showed relatively constant perfusate concentrations of HA
during 70 min of reperfusion, indicating an almost complete lack of function/viability of ECs
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(Fig. 1, bottom panel). Pretreatment of donors with MP or DMP after 24 h of preservation did
not cause any improvements in the liver uptake of HA (Fig. 1, bottom).
The kinetic parameters of HA in the Unpreserved and 8-h preservation groups are presented
in Table I. Cold preservation of livers from untreated rats for 8 h caused a significant (p<0.05,
ANOVA followed by Fisher's post-hoc) decrease (∼80%) in the E and Clh of HA, associated
with a substantial increase in the marker half life, when compared with Unpreserved livers
(Table I). Although pretreatment of donors with MP caused a significant decrease (36%) in
the half life of HA, the MP-induced increase in the E and Clh of HA did not reach statistical
significance (Table I). In contrast, pretreatment of donors with DMP (DMP-8) significantly
increased (by ∼ 140%) both E and Clh of HA, resulting in a 60% decrease in its half life,
compared with untreated livers (Control-8) (Table I).
Due to the lack of an appreciable decline in the perfusate HA concentrations after 24 h of
preservation (Fig. 1, bottom), the HA kinetic parameters were not calculated for these groups.
The bile flow rates of IPRLs in Control, MP and DMP groups following 8 and 24 h of cold
preservation along with the flow rate in Unpreserved livers are shown in Figure 2. The average
bile flow rate in the Unpreserved livers was 0.36 ± 0.05 ml/h. Neither preservation time nor
pretreatment with MP or DMP resulted in altered bile flow rates, when compared with
Unpreserved livers (Fig. 2).
Effect of MP or DMP on Cold Preservation-Reperfusion Injury following OLT
The plots of percent survival as a function of post-transplantation time for Control, MP, and
DMP groups are shown in Fig. 3. The seven-day survival of transplant recipients grafted with
24-h preserved livers harvested from untreated (Control) donors was 50%. Treatment of donors
with MP did not significantly alter the survival of animals (60% in the MP group). In contrast,
treatment of donors with DMP significantly (p<0.05, log rank test applied to Kaplan Meier
survival curves) increased survival to 100% (Fig. 3).
The blood glucose concentration measured immediately after the completion of transplantation
surgery was 122 ± 52 mg/dl in the untreated Control group. Treatment of donors with MP did
not significantly alter the blood glucose concentrations (174 ± 18 mg/dl). In contrast, DMP
pretreatment significantly (p<0.05, one-way ANOVA, with Fisher's post-hoc) increased the
blood glucose levels by a factor of two to 236 ± 41 mg/dl.
The plasma concentrations of TNF-α and HA at 1 and 6 h following transplantation are shown
in Fig. 4. Generally, an increase in the perfusion time caused a significant increase in the plasma
concentrations of both TNF-α (Fig. 4, top) and HA (Fig. 4, bottom). Treatment of donors with
MP did not significantly alter the plasma TNF-α concentrations. In contrast, DMP pretreatment
significantly (p<0.05, two-way ANOVA, with Fisher's post-hoc) decreased the plasma levels
of TNF-α, compared with untreated controls (Fig. 4, top). As for HA, consistent with the IPRL
data for 24 h of cold preservation (Fig. 1, bottom), no effects of MP or DMP pretreatment was
observed in vivo either at 1 or 6 h post-transplantation (Fig. 4, bottom).
The plasma concentrations of AST and ALT in transplanted animals are presented in Fig. 5.
Following 1 h of reperfusion, the plasma concentrations of AST (Fig. 5, top) and ALT (Fig. 5,
bottom) in untreated controls were 3560 ± 1110 and 1130 ± 195 IU/ml, respectively.
Reperfusion for 6 h further increased the ALT concentrations by factor of 3 (p<0.01). However,
a two-fold increase in the AST concentrations after 6 h of reperfusion did not reach statistical
significance. Treatment of donors with either MP or DMP did not significantly alter the plasma
ALT or AST concentrations (Fig. 5).
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DISCUSSION
Methylprednisolone, a glucocorticoid, is currently used as an anti-inflammatory and
immunosuppressive drug (14). Most of the long-term effects of corticosteroids are probably
mediated by their action on the intracellular glucocorticoid receptors (14). Activation of
glucocorticoid receptors initiates alterations in nuclear factor (NF)-κB activation, which is
critical for the expression of various proinflammatory cytokines following ischemic insults
(14). Therefore, glucocorticoids, such as MP, may be of therapeutic value in reducing the
inflammatory processes associated with ischemia-reperfusion injury.
While MP has a potent anti-inflammatory activity, it distributes rapidly to multiple organs
(6,15), resulting in the lack of tissue specificity in its effects. Tissue specificity in action is
critical in conditions wherein only a specific tissue/organ undergoes ischemic injury, like the
liver following cold preservation prior to transplantation. Therefore, development of strategies
aimed at selectively delivering corticosteroids to the liver may help in attenuation of cold IR
injury. Indeed, recent studies from our laboratory (4,5) have shown that pretreatment of donors
with a liver-targeted prodrug of MP (DMP) results in selective accumulation of DMP in the
liver and improvement in cold preservation injury in an IPRL model.
Previous reports have suggested that all three major liver cells, namely KCs (1,2), ECs (1,2),
and hepatocytes (16) contribute to the preservation-induced IR injury. In our recent studies
using IPRL models (4,5), we demonstrated the superiority of DMP over equimolar doses of
the parent drug MP as a donor pretreatment in reducing cold preservation-induced KC
activation (reduction of cytokine release into the perfusate) and improvement of hepatocyte
functions (increased biliary excretion of indocyanine green). However, the potential effects of
MP or DMP on preservation-induced damage to ECs are not known. Our present IPRL studies
demonstrating the positive effects of DMP on IR-induced EC damage (Fig. 1 and Table I) are
in agreement with the superior protective effects of the prodrug, in comparison with the parent
drug, on KC (4) and hepatocytes (5), observed before in an IPRL model of preservation-induced
injury. However, in contrast to the effects of DMP on KCs and hepatocytes, the protective
effects of the prodrug on ECs, observed after 8 h of preservation, were lost by an extension of
the preservation time to 24 h (Fig. 1). Indeed, after 24 h of cold preservation, no uptake of HA
into the preserved livers was observed, regardless of the donor pretreatment (Fig. 1, bottom),
indicating a total loss of viability of ECs during 24 h of cold preservation. Cold IR-induced
rapid and complete loss of EC function, observed in our study after 24 h of preservation (Fig.
1), has also been reported by others (2,17,18). Nevertheless, our current IPRL studies (Fig. 1)
suggest that MP or DMP pretreatment may be protective of ECs only following shorter
durations of cold preservation when these cells are injured to a lesser extent.
The protective effect of DMP on EC function, as assessed by HA clearance in the IPRL studies
(Fig. 1 and Table I), may be due to its direct action on ECs and/or an indirect action via KC
inactivation. Studies (19) conducted on corneal ECs have demonstrated that corticosteroids
inhibit the decrease in viability of these cells during preservation. Therefore, the enhanced EC
function observed in our current study (Fig. 1 and Table I) may be, at least in part, due to the
direct protective actions of regenerated MP on ECs. Secondly, it has been demonstrated (1,2,
18) that cytokines like TNF-α and reactive oxygen radicals, released following cold IR-
mediated KC activation, are cytotoxic to ECs. Consequently, agents that inactivate KCs also
cause a decrease in EC damage (17,20). Given that DMP decreases activation of KCs as shown
elsewhere by us (4) and also in this study (Fig. 4, top), the enhancement of EC viability may
also be due to DMP-induced decrease in KC activation in those livers. Further studies are
required to elucidate the exact mechanisms involved in EC protection by DMP.
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Overall, our present studies on EC function (Fig. 1 and Table I) and previous studies on the
functions of KCs (4) and hepatocytes (5) in an IPRL model suggest that DMP and, to a lesser
degree, MP may be effective as donor pretreatment to reduce cold preservation-induced liver
damage in transplantation. Therefore, we also conducted in vivo studies in a syngeneic rat liver
transplantation model. Previous studies have shown that cold preservation in UW for ≤ 24 h
along with anhepatic times of ≤ 14 min does not significantly affect graft survival in rat liver
transplantation models, whereas a 24 h preservation time coupled with an anhepatic time of
18−21 min significantly reduces graft survival (13). Therefore, we selected a preservation time
of 24 h and an anhepatic time of 19 min in these studies to induce sufficient IR injury in
vivo. Consistent with our hypothesis, donor pretreatment with DMP significantly increased
survival of the transplanted grafts from 50% to 100 on day 7 post-transplantation, whereas MP
pretreatment was not effective (Fig. 3).
The DMP-induced improvement in survival of animals after transplantation (Fig. 3) was
associated with a decrease in the plasma TNF-α concentrations (Fig. 4, top), suggestive of a
reduction in KC activation. This is in agreement with our previous IPRL studies, which
demonstrated that DMP and MP pretreatments reduced TNF-α concentrations in the perfusate
by 75% and 34%, respectively, after 24 h of cold preservation (4). Additionally, the
significantly higher concentrations of glucose immediately after OLT using DMP-pretreated
livers, compared with vehicle- or MP-pretreated livers (See Results), is in agreement with the
increased survival in this group (Fig. 3). Cold IR injury depresses the high-energy nucleotide
content and increases oxidant stress in the hepatocytes, leading to imbalances in energy
metabolism and subsequent hepatocellular dysfunction (16,21,22). Indeed, studies have
demonstrated a direct relationship between glycogen or adenosine triphosphate concentrations
in liver allografts and post operative graft function or survival (23,24). Therefore, the protective
effects of DMP on graft survival (Fig. 3) may be due, at least in part, to the improved
hepatocellular energy metabolism as evidenced by the increased post-operative blood glucose
concentrations in this group (See Results). Additionally, although not studied here, our previous
IPRL studies (5) clearly showed that DMP pretreatment increased the biliary excretion of ICG,
a marker of graft hepatocytes function, by > 12 fold in livers preserved in cold for 24 h, whereas
MP was ineffective. Overall, these data suggest that the improvement in graft survival observed
in our in vivo study after DMP pretreatment (Fig. 3) is most likely due to inactivation of KCs
and possibly improvement of hepatocytes functions by the prodrug.
In contrast to the TNF-α and glucose concentrations, the plasma concentrations of HA (Fig. 4,
bottom), AST (Fig. 5, top), and ALT (Fig. 5, bottom) were not significantly affected by
pretreatment with either MP or DMP in our transplanted rats. The OLT results for HA (Fig. 4,
bottom) were expected because our IPRL studies clearly showed an almost total loss of EC
function after 24 h of cold preservation, regardless of donor pretreatment (Fig. 1, bottom).
Additionally, the lack of effects of pretreatments on the liver injury markers (AST and ALT)
suggests involvement of extra-hepatic factors in the observed improved survival (Fig. 3).
Following cold IR, in addition to the hepatic injury by preservation and subsequent reperfusion,
extrahepatic factors like pulmonary injury and systemic endotoxin-like shock syndrome may
also play a major role in the mortality of transplant recipients (25-29). Prolonged intestinal
congestion during the anhepatic time followed by reperfusion results in translocation of
intestinal endotoxin into the portal circulation. Subsequently, exposure of liver KCs to
endotoxin causes KC activation, resulting in the release of cytokines like TNF-α into the
systemic circulation (25-27,30). TNF-α, along with other cytokines, may damage extrahepatic
organs like lung, resulting in mortality observed in transplant recipients (28,29,31). Therefore,
improvement in survival despite a lack of improvement in liver injury markers may be due to
decreased extra-hepatic organ toxicity caused by reduced TNF-α in the DMP group (Fig. 4,
top). Indeed, Urata et al. in a rat OLT model with an identical portal vein clamping time,
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demonstrated that decreased TNF-α production, caused by pretreatment with KC depleting or
inactivating agents resulted in improved 10-day survival despite a lack of improvement in
hepatic biochemical (AST and lactate dehydrogenase) indices (32). In addition, they also
reported significant decreases in pulmonary injury in the KC depleted livers, further confirming
that pulmonary and other extrahepatic organ injuries have a major influence in survival
following 24-h preservation in a rat OLT model (32). Therefore, it is likely that the DMP-
induced improved survival rate observed in our study (Fig. 3) is, in part, a result of decreased
damage to the lungs and/or other extrahepatic tissues.
Although not determined in this study, the time course of the liver exposure to DMP or MP
after administration of a single 5-mg/kg dose of the prodrug or the parent drug to rats has been
reported in several studies before (4-6,33). Based on one of these studies (6), 2 h after the in
vivo injection of a single 5-mg/kg dose of MP, the liver concentration of the drug was ∼0.4
μg/g. However, after the administration of an equivalent dose of the prodrug, DMP achieved
a liver concentration (∼40 μg/g) that was almost 100 fold higher than that after the MP injection.
Additionally, the concentration of the regenerated MP after DMP injection at this time point
(2 h) was ∼0.3 μg/g. Further studies (4,5) in the livers isolated 2 h after a single 5-mg/kg dose
of MP or DMP and subjected to 24 h of ex vivo preservation (similar to the current study)
showed no detectable concentration of MP after the parent drug injection. However, after DMP
injection, relatively high concentrations of DMP persisted in the preserved livers, slowly
regenerating the active drug. Therefore, the difference between MP and DMP in their effects
on graft survival (Fig. 3) is most likely due to persistence of the drug in the liver after the
prodrug injection.
CONCLUSION
Pretreatment of liver donors with a liver-targeted dextran prodrug of MP significantly increased
graft survival following transplantation of livers subjected to cold preservation for 24 h.
However, an equivalent dose of the parent drug was ineffective. The protective effect of DMP
on preservation-induced injury appears to be due to a reduction in the systemic concentrations
of TNF-α and an increase in the glucose production by the graft. Pretreatment of donors with
DMP may decrease cold IR damage and favorably influence the outcome of liver
transplantation.
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Figure 1.
The perfusate concentration-time courses of hyaluronic acid (HA) in isolated livers subjected
to 8 (top panel) or 24 h (bottom panel) of cold ischemia followed by 70 min of warm
reperfusion. Similar profiles in Unpreserved controls are provided for reference. Rats were
pretreated intravenously, 2 h prior to liver harvest, with a single 5-mg/kg dose (MP equivalent)
of MP or DMP or with saline (Control) (n=3−4/group). Symbols and bars represent the average
and standard deviation values, respectively.
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Figure 2.
The bile flow rates in isolated livers subjected to 0, 8, or 24 h of cold ischemia followed by 70
min of warm reperfusion. Rats were pretreated intravenously, 2 h prior to liver harvest, with a
single 5-mg/kg dose (MP equivalent) of MP or DMP or with saline (Control) (n=3−4/group).
Symbols and bars represent the average and standard deviation values, respectively.
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Figure 3.
Percent survival curves of transplanted animals receiving livers preserved for 24 h in UW
solution. Donor rats were pretreated with a single 5-mg/kg i.v. dose of MP or DMP or with
saline (Control) 2−3 h prior to graft harvest (n=8/group).
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Figure 4.
Plasma concentrations of TNF-α (top) and hyaluronic acid (HA) (bottom) in OLT recipients
at 1 and 6 h after implantation of livers preserved for 24 h. Donor rats were pretreated with a
single 5-mg/kg i.v. dose of MP or DMP or with saline (Control) 2−3 h prior to graft harvest.
Columns and bars represent mean and standard deviation values, respectively (n=3−4/group).
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Figure 5.
Plasma concentrations of AST (top) and ALT (bottom) in OLT recipients at 1 and 6 h after
implantation of livers preserved for 24 h. Donor rats were pretreated with a single 5-mg/kg i.v.
dose of MP or DMP or with saline (Control) 2−3 h prior to graft harvest. Columns and bars
represent mean and standard deviation values, respectively (n=3−4/group).
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Table I
Kinetic Parameters (Mean ± SD) of Hyaluronic Acid in Isolated Perfused Rat Livers Pretreated with Vehicle
(Control), Methylprednisolone (MP), or Dextran-Methylprednisolone (DMP) after 0 (Unpreserved) or 8 h of
Cold Preservation and 70 min of Warm Reperfusion
Parameter Preservation Time (h)
0 8
Unpreserved Control MP DMP
Clearance (ml/min) 12 ± 2 2.2 ± 0.8a 3.5 ± 0.6a 5.1 ± 2.2a,b
Extraction Ratio 0.40 ± 0.07 0.072 ± 0.025a 0.12 ± 0.02a 0.17 ± 0.07a,b
Terminal Half-life (min) 6.9 ± 0.6 45 ± 14a 29 ± 8a,b 20 ± 10b
a
Significantly different from 0 h preserved group: p<0.05, ANOVA, followed by Fisher's post-hoc test.
b
Significantly different from saline-treated preserved group: p<0.05, ANOVA, followed by Fisher's post-hoc test.
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